These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 34204950)

  • 21. Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations.
    Preto A; Gonçalves J; Rebocho AP; Figueiredo J; Meireles AM; Rocha AS; Vasconcelos HM; Seca H; Seruca R; Soares P; Sobrinho-Simões M
    BMC Cancer; 2009 Oct; 9():387. PubMed ID: 19878585
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E.
    Lee MH; Lee SE; Kim DW; Ryu MJ; Kim SJ; Kim SJ; Kim YK; Park JH; Kweon GR; Kim JM; Lee JU; De Falco V; Jo YS; Shong M
    J Clin Endocrinol Metab; 2011 Jan; 96(1):E19-30. PubMed ID: 20926530
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epigenetically upregulated WIPF1 plays a major role in BRAF V600E-promoted papillary thyroid cancer aggressiveness.
    Zhang T; Shen X; Liu R; Zhu G; Bishop J; Xing M
    Oncotarget; 2017 Jan; 8(1):900-914. PubMed ID: 27863429
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting NG2 relieves the resistance of BRAF-mutant thyroid cancer cells to BRAF inhibitors.
    Sui F; Wang G; Liu J; Yuan M; Chen P; Yao Y; Zhang S; Ji M; Hou P
    Cell Mol Life Sci; 2024 May; 81(1):238. PubMed ID: 38795180
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination
    Gunda V; Ghosh C; Hu J; Zhang L; Zhang YQ; Shen M; Kebebew E
    Thyroid; 2023 Oct; 33(10):1201-1214. PubMed ID: 37675898
    [No Abstract]   [Full Text] [Related]  

  • 26. Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma.
    Dasgupta T; Olow AK; Yang X; Hashizume R; Nicolaides TP; Tom M; Aoki Y; Berger MS; Weiss WA; Stalpers LJ; Prados M; James CD; Mueller S; Haas-Kogan DA
    J Neurooncol; 2016 Feb; 126(3):385-93. PubMed ID: 26384810
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
    Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
    Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The BRAFT1799A mutation confers sensitivity of thyroid cancer cells to the BRAFV600E inhibitor PLX4032 (RG7204).
    Xing J; Liu R; Xing M; Trink B
    Biochem Biophys Res Commun; 2011 Jan; 404(4):958-62. PubMed ID: 21185263
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting Autophagy Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.
    Wang W; Kang H; Zhao Y; Min I; Wyrwas B; Moore M; Teng L; Zarnegar R; Jiang X; Fahey TJ
    J Clin Endocrinol Metab; 2017 Feb; 102(2):634-643. PubMed ID: 27754804
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential effects of MAPK pathway inhibitors on migration and invasiveness of BRAF(V600E) mutant thyroid cancer cells in 2D and 3D culture.
    Ingeson-Carlsson C; Martinez-Monleon A; Nilsson M
    Exp Cell Res; 2015 Nov; 338(2):127-35. PubMed ID: 26384551
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BRAF associated autophagy exploitation: BRAF and autophagy inhibitors synergise to efficiently overcome resistance of BRAF mutant colorectal cancer cells.
    Goulielmaki M; Koustas E; Moysidou E; Vlassi M; Sasazuki T; Shirasawa S; Zografos G; Oikonomou E; Pintzas A
    Oncotarget; 2016 Feb; 7(8):9188-221. PubMed ID: 26802026
    [TBL] [Abstract][Full Text] [Related]  

  • 32.
    Tan J; Liu R; Zhu G; Umbricht CB; Xing M
    Proc Natl Acad Sci U S A; 2020 Jul; 117(27):15846-15851. PubMed ID: 32561648
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.
    Duquette M; Sadow PM; Husain A; Sims JN; Antonello ZA; Fischer AH; Song C; Castellanos-Rizaldos E; Makrigiorgos GM; Kurebayashi J; Nose V; Van Hummelen P; Bronson RT; Vinco M; Giordano TJ; Dias-Santagata D; Pandolfi PP; Nucera C
    Oncotarget; 2015 Dec; 6(40):42445-67. PubMed ID: 26636651
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phenformin enhances the therapeutic benefit of BRAF(V600E) inhibition in melanoma.
    Yuan P; Ito K; Perez-Lorenzo R; Del Guzzo C; Lee JH; Shen CH; Bosenberg MW; McMahon M; Cantley LC; Zheng B
    Proc Natl Acad Sci U S A; 2013 Nov; 110(45):18226-31. PubMed ID: 24145418
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant.
    Liu D; Hu S; Hou P; Jiang D; Condouris S; Xing M
    Clin Cancer Res; 2007 Feb; 13(4):1341-9. PubMed ID: 17317846
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel dual AMPK activator/mTOR inhibitor inhibits thyroid cancer cell growth.
    Plews RL; Mohd Yusof A; Wang C; Saji M; Zhang X; Chen CS; Ringel MD; Phay JE
    J Clin Endocrinol Metab; 2015 May; 100(5):E748-56. PubMed ID: 25710562
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    Zou M; Baitei EY; BinEssa HA; Al-Mohanna FA; Parhar RS; St-Arnaud R; Kimura S; Pritchard C; Alzahrani AS; Assiri AM; Meyer BF; Shi Y
    Cancer Res; 2017 Apr; 77(8):2161-2172. PubMed ID: 28242615
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MicroRNA-150-5p affects cell proliferation, apoptosis, and EMT by regulation of the BRAF
    Yan R; Yang T; Zhai H; Zhou Z; Gao L; Li Y
    J Cell Biochem; 2018 Nov; 119(11):8763-8772. PubMed ID: 30126001
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oncogenic BRAF inhibitor UAI-201 induces cell cycle arrest and autophagy in BRAF mutant glioma cells.
    Ahn JH; Lee YW; Ahn SK; Lee M
    Life Sci; 2014 May; 104(1-2):38-46. PubMed ID: 24721513
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Akt inhibitor MK2206 synergizes, but perifosine antagonizes, the BRAF(V600E) inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cells.
    Liu R; Liu D; Xing M
    J Clin Endocrinol Metab; 2012 Feb; 97(2):E173-82. PubMed ID: 22090271
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.